相似文献
1
Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse.
J Virol. 2009 Aug;83(16):8254-8. doi: 10.1128/JVI.00580-09. Epub 2009 Jun 3.
2
Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse.
J Virol. 2012 Jan;86(1):114-20. doi: 10.1128/JVI.05590-11. Epub 2011 Oct 19.
3
HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model.
Retrovirology. 2006 Nov 1;3:76. doi: 10.1186/1742-4690-3-76.
4
Establishment of a Novel Humanized Mouse Model To Investigate Activation and Depletion of Patient-Derived HIV Latent Reservoirs.
J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.02051-18. Print 2019 Mar 15.
5
Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
PLoS Pathog. 2020 Aug 25;16(8):e1008791. doi: 10.1371/journal.ppat.1008791. eCollection 2020 Aug.
6
A Simple Mouse Model for the Study of Human Immunodeficiency Virus.
AIDS Res Hum Retroviruses. 2016 Feb;32(2):194-202. doi: 10.1089/AID.2015.0211. Epub 2015 Dec 17.
7
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.
Mol Ther. 2011 Dec;19(12):2228-38. doi: 10.1038/mt.2011.207. Epub 2011 Sep 27.
8
Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.01389-16. Print 2017 Feb 1.
9
Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
Sci Rep. 2020 Dec 18;10(1):22286. doi: 10.1038/s41598-020-79002-w.
10
CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
J Clin Virol. 2012 Jan;53(1):29-32. doi: 10.1016/j.jcv.2011.09.018. Epub 2011 Oct 22.
引用本文的文献
1
Inducing Long-Term HIV-1 Latency in the TKO-BLT Mouse Model.
Methods Mol Biol. 2022;2407:253-273. doi: 10.1007/978-1-0716-1871-4_18.
2
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays.
MAbs. 2022 Jan-Dec;14(1):1993522. doi: 10.1080/19420862.2021.1993522.
3
Endogenous retroviruses promote homeostatic and inflammatory responses to the microbiota.
Cell. 2021 Jul 8;184(14):3794-3811.e19. doi: 10.1016/j.cell.2021.05.020. Epub 2021 Jun 23.
4
The Contributions of Clinical Pharmacology to HIV Cure Research.
Clin Pharmacol Ther. 2021 Aug;110(2):334-345. doi: 10.1002/cpt.2237. Epub 2021 Apr 18.
5
Advances in Humanized Mouse Models to Improve Understanding of HIV-1 Pathogenesis and Immune Responses.
Front Immunol. 2021 Mar 5;11:617516. doi: 10.3389/fimmu.2020.617516. eCollection 2020.
6
A pathogenic role of plasmacytoid dendritic cells in autoimmunity and chronic viral infection.
J Exp Med. 2019 Sep 2;216(9):1974-1985. doi: 10.1084/jem.20181359. Epub 2019 Aug 16.
7
Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice.
Curr HIV/AIDS Rep. 2019 Jun;16(3):224-229. doi: 10.1007/s11904-019-00444-7.
8
Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review.
Pathog Immun. 2016 May 31;1(1):41-67. doi: 10.20411/pai.v1i1.104. eCollection 2016.
9
Humanized Mice as Unique Tools for Human-Specific Studies.
Arch Immunol Ther Exp (Warsz). 2018 Aug;66(4):245-266. doi: 10.1007/s00005-018-0506-x. Epub 2018 Feb 7.
10
Comparative Analysis of Tat-Dependent and Tat-Deficient Natural Lentiviruses.
Vet Sci. 2015 Sep 29;2(4):293-348. doi: 10.3390/vetsci2040293.
本文引用的文献
1
RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.
J Virol. 2008 Dec;82(24):12145-53. doi: 10.1128/JVI.01105-08. Epub 2008 Oct 8.
2
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.
3
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.
4
Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.
Virology. 2008 Apr 10;373(2):342-51. doi: 10.1016/j.virol.2007.11.020. Epub 2008 Jan 18.
5
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
PLoS Med. 2008 Jan 15;5(1):e16. doi: 10.1371/journal.pmed.0050016.
6
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
J Virol. 2007 Nov;81(22):12145-55. doi: 10.1128/JVI.01301-07. Epub 2007 Sep 12.
7
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33. doi: 10.1097/QAI.0b013e318157131c.
8
Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
PLoS One. 2007 Aug 1;2(7):e655. doi: 10.1371/journal.pone.0000655.
9
Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
J Clin Pharmacol. 2007 Jun;47(6):751-9. doi: 10.1177/0091270007300951.
10
Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.
J Exp Med. 2007 Apr 16;204(4):705-14. doi: 10.1084/jem.20062411. Epub 2007 Mar 26.
Zotero 插件